查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011044

外陰疼痛治療市場：依治療方法、給藥途徑和最終用戶分類－2026-2032年全球市場預測

Vulvodynia Treatment Market by Treatment Type, Administration Route, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，外陰疼痛治療市場價值將達到 667.5 億美元，到 2026 年將成長至 730.4 億美元，到 2032 年將達到 1,295.1 億美元，複合年成長率為 9.93%。

主要市場統計數據
基準年 2025 667.5億美元
預計年份：2026年 730.4億美元
預測年份 2032 1295.1億美元
複合年成長率 (%) 9.93%

簡要概述外陰疼痛的臨床複雜性、醫療保健服務挑戰以及對尋求針對性解決方案的相關人員的策略意義。

外陰疼痛是一種複雜且多方面的臨床挑戰，涉及疼痛管理、婦科護理和慢性病管理等多個領域。患者往往需要經歷漫長的診斷過程，症狀表現多樣，對治療方法的反應也各不相同。臨床醫生正在調整診療通訊協定，以便根據症狀表現型和治療反應更好地對患者進行分層，而研究人員則繼續探索其潛在的病理學，涉及神經系統、發炎和肌肉骨骼系統等領域。

變革性的臨床、監管和商業性趨勢正在重塑外陰炎治療的治療範式、證據預期和護理服務模式。

近年來，在臨床和商業領域，外陰疼痛的識別、研究和治療發生了顯著變化。診斷框架正朝著多方面評估的方向發展，整合疼痛定位、心理社會評估和骨盆底功能測試，從而為更個人化的治療方法方案鋪平道路。同時，神經調控技術、具有標靶遞送機制的局部製劑以及復健方法的進步，也拓展了臨床醫師可根據患者個別表現型製定治療方案的範圍。

美國近期關稅政策變化對外陰疼痛治療用品和服務的供應鏈、籌資策略和定價談判的影響。

貿易和關稅制度的政策變化可能會對與外陰疼痛治療相關的治療方法和臨床材料的供應、成本基礎和供應鏈設計產生重大影響。進口藥品活性成分、專用給藥裝置或成品外用和注射劑的關稅增加，可能會促使製造商重新評估籌資策略，並考慮將生產外包或供應商多元化，以緩解利潤率壓力。同時，經銷商和醫療保健系統可能會在臨床適用的情況下，將採購重點轉向國內替代方案。

將治療方法、給藥途徑和最終用戶醫療保健環境與開發、部署和交付考慮因素聯繫起來的精細細分見解。

細分為評估治療重點和商業化策略提供了一個結構化的觀點。根據治療類型，該領域將治療分為非藥物療法和藥物療法，這種區分體現在臨床試驗設計、支付方合作和治療路徑制定等方面。非藥物療法往往著重於復原和行為終點，而藥物療法則優先考慮生化標靶和耐受性。

美洲、歐洲、中東和非洲以及亞太地區在治療獲取促進因素、支付方框架和交付系統方面存在細微差異。

區域趨勢塑造了臨床實踐模式、報銷模式和供應鏈選擇，對獲得和接受外陰疼痛治療產生重大影響。在美洲，多樣化的支付方體系和強大的私人醫療保健網路強調療效比較、病患報告結果以及在門診和專科診療中可證實的價值。臨床醫生擴大採用多學科診療模式，製藥公司需要與各相關人員合作，以確保處方集納入和專科醫生的採納。

一家公司兼顧競爭與合作的策略。

競爭格局由成熟的製藥和醫療設備公司、新興的生技公司以及專注於整合醫療服務的服務供應商組成。成熟公司擁有規模優勢、豐富的監管經驗和廣泛的分銷網路，而小規模的創新者則提供差異化的作用機制、以患者為中心的治療平台和針對性的臨床項目。臨床服務供應商與藥物研發公司之間的合作日益普遍，這有助於收集更豐富的數據，並在真實的臨床環境中快速改善治療通訊協定。

製造商和供應商採取切實有效的措施，協調證據產生、供應彈性和相關人員參與，以實現成功實施。

產業領導者應優先考慮整合證據策略，使臨床試驗終點與臨床醫生和支付方重視的真實世界指標一致。投資於檢驗的患者報告結局 (PRO) 評估工具和縱向觀察性研究，將增強藥物推廣決策和臨床指南更新所依據的數據。同時，製藥公司在設計產品和醫療設備功能時，必須充分考慮最終用戶的人體工學，以支持患者自行用藥和看護者輔助的居家照護方案。

我們採用嚴謹的混合方法研究途徑，結合對臨床醫生的訪談、二手文獻的整合以及資料檢驗，為實際的臨床和商業性見解提供了支持。

本研究途徑，旨在全面了解臨床實踐、產品特性和給藥模式。主要研究包括對婦科和疼痛管理專科的臨床醫生、醫院和專科診所的採購經理以及負責治療藥物採購的供應鏈經理進行結構化訪談。這些訪談深入探討了影響臨床決策的因素、採購限制以及不同給藥途徑的營運要求。

我們從臨床、營運和區域需求等方面進行策略整合，以明確創新和實際應用能夠在哪些方面帶來醫療保健方面的實質改進。

目前外陰疼痛的治療格局呈現出臨床路徑不斷擴展、循證醫學要求不斷提高以及治療模式多樣化的特點，這些因素共同為創新和推廣應用創造了多種途徑。相關人員若能將產品開發與檢驗的、以病人為中心的療效指標結合，投資於穩健的供應鏈，並在實證醫學規劃的早期階段就與臨床醫師溝通，將更有利於影響治療標準，並確保相關療法在醫療機構中的應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 外陰疼痛治療市場（依治療方法分類）

  • 非藥物療法
  • 藥物治療

第9章：外陰疼痛治療市場（依給藥途徑分類）

  • 注射藥物
  • 口服
  • 外用

第10章：外陰疼痛治療市場：依最終用戶分類

  • 居家照護
    • 看護者援助
    • 自我管理
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 婦科診所
    • 疼痛管理診所

第11章：外陰疼痛治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：外陰疼痛治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 外陰疼痛治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國外陰疼痛治療市場

第15章 中國外陰疼痛治療市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • Bayer Aktiengesellschaft
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Grunenthal GmbH
  • Janssen Pharmaceuticals, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Pfizer Inc.
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, LLC
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-433BAD49EE73

The Vulvodynia Treatment Market was valued at USD 66.75 billion in 2025 and is projected to grow to USD 73.04 billion in 2026, with a CAGR of 9.93%, reaching USD 129.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 66.75 billion
Estimated Year [2026] USD 73.04 billion
Forecast Year [2032] USD 129.51 billion
CAGR (%) 9.93%

Concise contextual overview of vulvodynia clinical complexity, care delivery challenges, and strategic implications for stakeholders seeking targeted solutions

Vulvodynia presents a complex and multifaceted clinical challenge that intersects pain management, gynecology, and chronic care delivery. Patients frequently experience prolonged diagnostic journeys, heterogeneous symptom patterns, and variable responses to treatment modalities. Clinicians are adapting protocols to better stratify patients by symptom phenotype and treatment responsiveness, while researchers continue to explore underlying pathophysiology that spans neurological, inflammatory, and musculoskeletal domains.

Against this backdrop, stakeholders require a consolidated synthesis that translates emerging science into pragmatic clinical and commercial actions. The landscape increasingly rewards interventions that offer clear mechanistic rationale, tolerable safety profiles, and demonstrable improvements in patient-reported outcomes. Meanwhile, payers and providers demand evidence of long-term benefit and feasible pathways for integration into outpatient and home-based care models.

This summary frames the therapeutic environment in operational terms, highlighting critical decision points for product development, clinical adoption, and service design. It emphasizes where clinical need, scientific opportunity, and health system readiness align, and it outlines the strategic priorities that will matter most to manufacturers, clinicians, and health system leaders over the near term.

Transformative clinical, regulatory, and commercial dynamics reshaping treatment paradigms, evidence expectations, and care delivery models for vulvodynia care

Recent years have seen substantive shifts in how vulvodynia is recognized, investigated, and managed across clinical and commercial settings. Diagnostic frameworks have moved toward multimodal assessment that integrates pain mapping, psychosocial evaluation, and pelvic floor function testing, creating pathways for more personalized treatment selection. Concurrently, advances in neuromodulatory techniques, topical formulations with targeted delivery mechanisms, and rehabilitative approaches have broadened therapeutic options that clinicians can tailor to distinct patient phenotypes.

Regulatory emphasis on patient-centered outcomes and real-world evidence is reshaping development strategies, prompting sponsors to prioritize validated patient-reported outcome instruments and longitudinal observational data. Health systems have also increased adoption of integrated care pathways that combine specialist consultation, pelvic floor physiotherapy, and pain psychology, thereby reducing fragmentary care and improving continuity.

Commercially, manufacturers and service providers are aligning with value-based procurement trends by generating comparative effectiveness data and engaging early with formulary decision-makers. Supply chain resilience and nimble manufacturing approaches are gaining prominence, particularly for injectable and topical therapeutics that require cold chain or specialized distribution. Taken together, these shifts are creating an environment where innovation is measured not only by efficacy but also by ease of integration into existing clinical workflows and reimbursement frameworks.

How recent United States tariff shifts are influencing supply chains, procurement strategies, and pricing negotiation dynamics across vulvodynia treatment supply and services

Policy changes in trade and tariff regimes can exert practical effects on the availability, cost base, and supply chain design for therapies and clinical supplies relevant to vulvodynia care. Increased duties on imported active pharmaceutical ingredients, specialized delivery devices, or finished topical and injectable products can prompt manufacturers to reassess sourcing strategies and consider nearshoring or supplier diversification to mitigate margin pressure. In parallel, distributors and health systems may respond by adjusting procurement preferences toward domestically produced alternatives when clinically appropriate.

The cumulative impact of tariff adjustments has also influenced pricing negotiations and contracting approaches. Payers and integrated delivery networks are increasingly focused on total cost of ownership, which includes upstream procurement costs and downstream service utilization. As a result, manufacturers that demonstrate supply chain transparency, predictable lead times, and adaptive pricing mechanisms are better positioned in competitive formulary discussions and institutional tender processes.

Moreover, tariffs can accelerate strategic partnerships between clinical suppliers and local manufacturers to preserve continuity of supply for essential topical formulations, specialized applicators, and ancillary devices. In practice, organizations are prioritizing robust supplier qualification, dual sourcing, and inventory management policies to maintain clinical continuity while absorbing or reallocating incremental cost pressures caused by trade policy shifts.

Granular segmentation-driven insights linking treatment modality, administration route, and end-user care settings to development, adoption, and delivery considerations

Segmentation provides the structural lens through which therapeutic priorities and commercialization strategies should be evaluated. Based on Treatment Type, the field differentiates non-pharmacological approaches from pharmacological interventions, and this distinction informs clinical trial design, payer engagement, and care pathway development. Non-pharmacological modalities often emphasize rehabilitative and behavioral endpoints, whereas pharmacological options prioritize biochemical targets and tolerability profiles.

Based on Administration Route, the analysis spans injectable, oral, and topical formats, each carrying unique clinical, regulatory, and logistical implications. Injectable therapies may require administration in clinical settings and have different cold-chain and safety monitoring considerations; oral agents typically favor ease of use and home administration but face adherence and systemic side-effect considerations; topical formulations prioritize local effect with minimized systemic exposure and demand careful attention to vehicle design and skin tolerability.

Based on End User, the market is studied across Home Care, Hospitals, and Specialty Clinics. The Home Care segment is further considered across caregiver-assisted and self-administered options, which affect device ergonomics, patient education, and remote monitoring needs. The Hospitals segment considers private hospitals and public hospitals, reflecting diverse procurement rules, formulary processes, and care delivery models. The Specialty Clinics segment differentiates gynecology clinics and pain management clinics, each with distinct referral patterns, multidisciplinary collaboration norms, and expectations for evidence of clinical benefit.

Regional treatment adoption drivers, payer frameworks, and delivery-system nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence access

Regional dynamics shape clinical practice patterns, reimbursement models, and supply chain choices in ways that materially affect access to and adoption of vulvodynia therapies. In the Americas, heterogeneous payer systems and a strong private-provider network drive emphasis on comparative effectiveness, patient-reported outcomes, and demonstrable value in outpatient and specialty settings. Clinicians increasingly integrate multidisciplinary care models, and manufacturers must engage diverse stakeholders to secure formulary placement and specialist adoption.

In Europe, Middle East & Africa, variations in regulatory requirements and public procurement frameworks create differentiated pathways to market. National guidelines and regional reimbursement policies often guide clinical adoption, while local manufacturing and distribution partnerships can mitigate cross-border logistical complexity. Stakeholders in this region prioritize scalable models of care that can be adapted to both high-resource tertiary centers and lower-resource community settings.

In Asia-Pacific, rapid expansion of outpatient specialty services, growing investment in women's health research, and rising demand for accessible home-care solutions shape commercialization strategies. Local clinical practice patterns and payer evolution favor interventions that combine clinical efficacy with cost-conscious delivery models. Across all regions, collaboration with local clinical opinion leaders and targeted real-world evidence generation remain central to successful adoption and long-term integration.

Competitive and collaborative company strategies emphasizing evidence generation, delivery innovation, and strategic alliances to accelerate clinical adoption and access

Competitive dynamics reflect a mix of established pharmaceutical and device players, emerging specialty biotechs, and service providers focused on integrated care delivery. Established companies bring scale, regulatory experience, and broad distribution networks, while smaller innovators contribute differentiated mechanisms of action, patient-centric delivery platforms, and targeted clinical programs. Partnerships between clinical service providers and therapeutic developers are becoming more common, enabling richer data collection and faster iteration on real-world treatment protocols.

Manufacturers with robust clinical development capabilities are investing in evidence-generation strategies that emphasize validated patient-reported outcome measures and mechanistic biomarkers to support label claims and payer engagement. Meanwhile, device manufacturers and digital therapeutics companies are differentiating through human-centered design, remote monitoring features, and interoperability with electronic health records to facilitate adoption in outpatient and home settings.

Strategic alliances, licensing transactions, and targeted acquisitions continue to be primary routes for organizations to fill capability gaps, access specialized delivery technologies, or enter new geographic markets. Entities that combine clinical credibility with operational agility and a clear plan for post-launch support will have a competitive advantage in securing institutional adoption and physician endorsement.

Pragmatic, high-impact actions for manufacturers and providers to align evidence generation, supply resilience, and stakeholder engagement for successful adoption

Industry leaders should prioritize integrated evidence strategies that align clinical trial endpoints with real-world measures valued by clinicians and payers. Investing in validated patient-reported outcome instruments and longitudinal observational studies will strengthen dossiers used in formulary discussions and clinical guideline updates. In parallel, manufacturers must design product and device features with end-user ergonomics in mind to support both self-administered and caregiver-assisted home care options.

Operationally, companies should pursue supply chain resilience by diversifying suppliers, qualifying regional manufacturing partners, and establishing clear inventory management policies to address tariff volatility and distribution disruptions. Engaging early with payers and health systems to pilot value-based contracting or outcomes-linked agreements can reduce procurement friction and demonstrate long-term cost-effectiveness. Collaboration with specialty clinics and multidisciplinary care teams will facilitate streamlined referral pathways and support broader adoption across gynecology and pain management practices.

Finally, commercial teams must build clinician-facing education programs and post-launch support services that emphasize practical integration into clinical workflows, reimbursement navigation, and patient education. These investments will accelerate uptake, reduce discontinuation rates, and generate meaningful real-world data that can be leveraged for iterative improvement and payer negotiations.

Rigorous mixed-methods research approach combining clinician interviews, secondary literature synthesis, and data triangulation to underpin actionable clinical and commercial insights

The research approach combined qualitative and quantitative evidence streams to construct a holistic understanding of clinical practice, product attributes, and delivery models. Primary research included structured interviews with clinicians across gynecology and pain management specialties, procurement leads from hospitals and specialty clinics, and supply chain managers responsible for therapeutic sourcing. These discussions provided granular insights into clinical decision drivers, procurement constraints, and operational requirements for different administration routes.

Secondary research synthesized peer-reviewed literature, regulatory documentation, clinical guidelines, and product labeling to validate mechanistic rationale and safety profiles. Data triangulation reconciled findings across sources to ensure consistency and highlight areas of divergence that warrant further investigation. The methodology also incorporated analysis of clinical trial registries and observational study reports to contextualize evolving evidence streams.

Limitations include variability in reporting standards across observational studies and heterogeneity in clinical practice patterns across regions. To mitigate these constraints, the research applied conservative interpretation of heterogeneous datasets and emphasized cross-validated trends supported by multiple independent sources. Ethical considerations guided stakeholder engagement, ensuring confidentiality and adherence to relevant research conduct standards throughout primary data collection.

Strategic synthesis of clinical, operational, and regional imperatives that distills where innovation and pragmatic execution will drive meaningful improvements in care

The current therapeutic landscape for vulvodynia is characterized by expanding clinical pathways, evolving evidence expectations, and diverse delivery models that together create multiple avenues for innovation and adoption. Stakeholders who align product development with validated patient-centered outcomes, invest in supply chain robustness, and engage clinicians early in evidence planning will be best positioned to influence care standards and secure institutional adoption.

Operational agility, strategic partnerships, and a focus on practical integration into outpatient and home-care workflows will determine success in commercializing new therapies and delivery systems. Moreover, regional variations in regulatory and reimbursement environments necessitate tailored market-entry approaches that respect local procurement norms and clinical practice patterns. Evidence generation that emphasizes real-world effectiveness and long-term patient benefit will resonate strongly with payers and providers alike.

In summary, the opportunity for meaningful clinical impact is greatest where scientific innovation meets pragmatic delivery solutions. Organizations that execute with clarity on evidence, supply chain, and stakeholder engagement can both improve patient outcomes and establish durable clinical and commercial positions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vulvodynia Treatment Market, by Treatment Type

  • 8.1. Non-Pharmacological
  • 8.2. Pharmacological

9. Vulvodynia Treatment Market, by Administration Route

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Vulvodynia Treatment Market, by End User

  • 10.1. Home Care
    • 10.1.1. Caregiver Assisted
    • 10.1.2. Self Administered
  • 10.2. Hospitals
    • 10.2.1. Private Hospitals
    • 10.2.2. Public Hospitals
  • 10.3. Specialty Clinics
    • 10.3.1. Gynecology Clinics
    • 10.3.2. Pain Management Clinics

11. Vulvodynia Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Vulvodynia Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Vulvodynia Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Vulvodynia Treatment Market

15. China Vulvodynia Treatment Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Amneal Pharmaceuticals, Inc.
  • 16.7. Bayer Aktiengesellschaft
  • 16.8. Dr. Reddy's Laboratories Ltd.
  • 16.9. Eli Lilly and Company
  • 16.10. Endo International plc
  • 16.11. GlaxoSmithKline plc
  • 16.12. Glenmark Pharmaceuticals Limited
  • 16.13. Grunenthal GmbH
  • 16.14. Janssen Pharmaceuticals, Inc.
  • 16.15. Merz Pharma GmbH & Co. KGaA
  • 16.16. Pfizer Inc.
  • 16.17. Sanofi S.A.
  • 16.18. STADA Arzneimittel AG
  • 16.19. Sun Pharmaceutical Industries Limited
  • 16.20. Taro Pharmaceutical Industries Ltd.
  • 16.21. Teva Pharmaceutical Industries Ltd.
  • 16.22. Upsher-Smith Laboratories, LLC
  • 16.23. Viatris Inc.
  • 16.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY CAREGIVER ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY CAREGIVER ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY CAREGIVER ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SELF ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SELF ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GYNECOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GYNECOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GYNECOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. GCC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GCC VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. G7 VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. NATO VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NATO VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)